Nachrichten zur Neurocrine Biosciences Aktie

Neurocrine Partners With Xenon To Add New Early-Stage Pipeline Assets

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Xenon Pharma up 23% premarket on Neurocrine Bio partnership in epilepsy

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Xenon Pharmaceuticals to Host Conference Call and Webcast to Provide Corporate Update on License and Collaboration Agreement with Neurocrine Biosciences

BURNABY, British Columbia, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, announced…

Neurocrine Biosciences and Xenon Pharmaceuticals Announce Agreement to Develop First-in-Class Treatments for Epilepsy

Neurocrine Biosciences Gains Rights to XEN901, a Clinical Stage Selective Nav1.6 Sodium Channel Inhibitor, Being Developed for the Treatment of…

Neurocrine Biosciences and Xenon Pharmaceuticals Announce Agreement to Develop First-in-Class Treatments for Epilepsy

SAN DIEGO and BURNABY, British Columbia , Dec. 2, 2019 …

Neurocrine Biosciences to Present at Evercore ISI 2nd Annual HealthCONx Conference

SAN DIEGO , Nov. 26, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present…

Neurocrine Making The Most Of A Strong Ingrezza Launch

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Neurocrine Bounces Back With Authority, But Little Upside Appears Evident As New Year Approaches

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Neurocrine Biosciences, Inc. 2019 Q3 - Results - Earnings Call Presentation

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q3 2019 Results - Earnings Call Transcript

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Neurocrine Biosciences Inc (NBIX) Q3 2019 Earnings Call Transcript

NBIX earnings call for the period ending September 30, 2019....…

Neurocrine Biosciences (NBIX) Beats Q3 Earnings and Revenue Estimates

Neurocrine (NBIX) delivered earnings and revenue surprises of 19.70% and 5.16%, respectively, for the quarter ended September 2019. Do the…

Neurocrine Biosciences EPS misses by $0.09, beats on revenue

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2019 Financial Results

SAN DIEGO , Oct. 14, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced…

Neurocrine Biosciences Presents New Data Analyses Demonstrating Long-Term Effects of INGREZZA® (valbenazine) 40 mg Once-Daily in Patients with Tardive Dyskinesia at the 2019 Annual Psych Congress

SAN DIEGO , Oct. 4, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today…

Neurocrine Biosciences to Present Data Analyses Demonstrating the Long-Term Effectiveness of INGREZZA® (valbenazine) in Patients with Tardive Dyskinesia at the 2019 Annual Psych Congress

SAN DIEGO , Oct. 1, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced…

Neurocrine Biosciences Appoints David W. Boyer as Chief Corporate Affairs Officer

SAN DIEGO , Sept. 30, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced…

Neurocrine Biosciences Announces Appointment of Leslie V. Norwalk to Board of Directors

SAN DIEGO , Sept. 11, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced…

Neurocrine Biosciences (NBIX) Presents At Baird Global Healthcare Conference - Slideshow

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Neurocrine Biosciences to Present at Upcoming Healthcare Conferences

SAN DIEGO , Aug. 28, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced…

Is Neurocrine Biosciences (NBIX) a Great Growth Stock-

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure…

Darum ist die Aktie von Neurocrine Biosciences gestiegen

Die guten Ergebnisse des zweiten Quartals haben den Optimismus gegenüber dem kleinen Biotech angeheizt....…

Why Neurocrine (NBIX) Could Be Positioned for a Surge

Neurocrine (NBIX) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors....…

AbbVie Submits New Drug Application to US FDA for Investigational Elagolix for Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Women

NORTH CHICAGO, Ill. , Aug. 5, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global…

Neurocrine Executing Very Well With Its Lead Commercial Compound

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Neurocrine Biosciences, Inc. 2019 Q2 - Results - Earnings Call Slides

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Why Neurocrine Biosciences Stock Is Jumping Today

Strong second-quarter results announced after the close Monday boosted market optimism about this small biotech....…

Neurocrine Biosciences Posts Sizzling Sales Growth in Q2

Sales soared for the drug Ingrezza. And key pipeline developments are on the way....…

ALKS Settles Patent Suit, Once-Monthly Contraceptive In The Works, NBIX On Watch

Todays Daily Dose brings you news about financial results of Neurocrine, PerkinElmer, Medpace and Vapotherm; resolution of VIVITROL patent suit…

Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q2 2019 Results - Earnings Call Transcript

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Neurocrine Biosciences (NBIX) Q2 Earnings and Revenues Top Estimates

Neurocrine (NBIX) delivered earnings and revenue surprises of 54.17% and 14.59%, respectively, for the quarter ended June 2019. Do the…

Neurocrine Biosciences Reports Second Quarter 2019 Financial Results

SAN DIEGO , July 29, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced…

Should You Buy Neurocrine (NBIX) Ahead of Earnings-

Neurocrine (NBIX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season....…

FDA Accepts Neurocrines NDA for Parkinsons Disease Drug

The FDA accepts Neurocrines (NBIX) NDA for opicapone, developed as an adjunctive treatment to levodopa/carbidopa for patients with Parkinsons disease,…

The Daily Biotech Pulse: Neurocrines Parkinsons Drug Accepted For Review, Sunesis Offering, No Headaches For Biohavens Migraine Drug

Heres a roundup of top developments in the biotech space over the last 24 hours. read more...…